Who depends on China Resources Pharmaceutical Group
1 listed supplier reports China Resources Pharmaceutical Group as a customer worth 10% or more of their revenue, led by Gyre Therapeutics at 13%.
Get an email when China Resources Pharmaceutical Group's customer concentration changes
When a new annual report adds a 10% customer, drops one, or moves a share by 5 points or more, you get the change and the filing link. Up to 10 companies per address, no account, unsubscribe with one click.
Suppliers that depend on China Resources Pharmaceutical Group
Listed companies whose annual report names China Resources Pharmaceutical Group as a customer worth 10% or more of their revenue. If China Resources Pharmaceutical Group cuts orders or switches supplier, these are the companies that feel it.
| Supplier | Its revenue from this company | Change vs prior year | History | Latest filing |
|---|---|---|---|---|
| Gyre TherapeuticsGYRE | 13% | from 14% | 4 years | FY 2025 · filed 13 Mar 2026 |
About this data
US-listed companies must disclose revenue from any single customer that reaches 10% of their total (ASC 280). ShadowGraph reads these disclosures from the XBRL data of every 10-K and 20-F we scan, keeps one value per fiscal year (restatements replace earlier values) and links each number to its filing. Companies that describe a customer only as "Customer A" are not listed by name. Figures are as reported; nothing here is investment advice.
All companies · Latest dependency shifts · Bulk data and API